截至2025年一季报，石药集团营业总收入70.15亿元、净利润14.78亿元。 本文源自：金融界 8月1日，石药集团(01093)盘中上涨3.83%，截至09:44，报10.3元/股，成交3.18亿元。 石药集团有限公司是香港的一家医药上市企业，主要业务为成药和原料药生产，并以创新药为核心发展 战略，在神经系统疾病、抗肿瘤、抗感染及心血管疾病等治疗领域具有强大的产品组合。同时该公司拥 有一支国际化的研发团队，专注于小分子靶向药物、纳米药物、单抗药物、双抗药物、抗体偶联药物以 及免疫领域生物药物的发现、研究及开发。 作者：行情君 ...

港股创新药概念股盘初冲高，石药集团(01093.HK)涨超5%，亚盛医药(06855.HK)涨超4%，四环医药 (00460.HK)、丽珠医药(01513.HK)等跟涨。 ...

Group 1 - The core viewpoint of the news is that CSPC Pharmaceutical Group has entered into an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development, production, and commercialization of the oral small molecule GLP-1 receptor agonist SYH2086, which has led to a significant increase in the company's stock price [1] - CSPC will receive up to $2.075 billion in total consideration, including an upfront payment of $120 million and potential milestone payments based on development, regulatory, and commercial achievements, as well as sales royalties based on annual net sales of SYH2086 [1] - The stock price of CSPC increased by 6.25% to HKD 10.54, with a trading volume of HKD 613 million at the time of reporting [1] Group 2 - Huatai Securities highlighted that the recent business development (BD) surpasses market expectations, showcasing CSPC's strong R&D and BD capabilities in the metabolic platform [2] - The company is in advanced discussions for a significant product, EGFR ADC, which is expected to become an important benchmark for domestic ADCs going abroad [2] - There are still important early-stage technology platforms with licensing expectations, and the sales and development potential of some key products (such as KN026 and PD-1/IL-15) remains to be reassessed [2]

Group 1 - The core viewpoint of the news is that CSPC Pharmaceutical Group has entered into an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development, production, and commercialization of the oral small molecule GLP-1 receptor agonist SYH2086, which has led to a significant increase in the company's stock price [1] - CSPC will receive up to $2.075 billion in total consideration, including an upfront payment of $120 million and potential milestone payments based on development, regulatory, and commercial achievements, as well as a high double-digit sales royalty based on annual net sales of SYH2086 [1] - The stock price of CSPC increased by 6.25% to HKD 10.54, with a trading volume of HKD 613 million, indicating strong market interest following the announcement [1] Group 2 - Huatai Securities highlighted that the licensing deal exceeded market expectations, showcasing CSPC's strong research and business development capabilities in the metabolic platform [2] - The company is in advanced discussions for a significant product, EGFR ADC, which is expected to become an important benchmark for domestic ADCs going abroad [2] - There are still important early-stage technology platforms with licensing expectations, and the sales and development potential of some key products (such as KN026 and PD-1/IL-15) remains to be reassessed [2]

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown strong performance, with significant increases in constituent stocks and the Hang Seng Healthcare ETF, driven by ongoing innovation and M&A activities in the pharmaceutical sector [3][4]. Group 1: Market Performance - As of August 1, 2025, the HSHCI rose by 1.15%, with notable gains from stocks such as Yaoshi Bang (up 4.87%) and Gushengtang (up 4.62%) [3]. - The Hang Seng Healthcare ETF (513060) increased by 1.46%, with a latest price of 0.7 yuan, and has accumulated a 4.58% rise over the past week [3]. - The ETF recorded a turnover rate of 5.66% and a trading volume of 4.53 billion yuan, with an average daily trading volume of 33.29 billion yuan over the past week, ranking first among comparable funds [3][4]. Group 2: Fund Growth and Performance - The Hang Seng Healthcare ETF saw a significant scale increase of 27.99 million yuan over the past week, placing it in the top third of comparable funds [4]. - The ETF's latest financing buy-in amount reached 288 million yuan, with a financing balance of 218 million yuan [4]. - Since its inception, the ETF has achieved a net value increase of 31.51% over the past two years, ranking 16th out of 90 QDII equity funds [4]. Group 3: Valuation and Index Composition - The HSHCI's latest price-to-earnings ratio (PE-TTM) stands at 32.12, indicating a valuation below 83.19% of the historical range over the past three years, suggesting it is at a historical low [5]. - The top ten weighted stocks in the HSHCI account for 62.14% of the index, including companies like BeiGene and WuXi Biologics [5].

比亚迪股份-R(81211)、中国海洋石油-R(80883)、美团-WR(83690)上一交易日沽空比率位于前三位，分 别为96.88%、80.42%、75.34%。美团-W(03690)、阿里巴巴-SW(09988)、快手-W(01024)的沽空金额位 居前三，分别为34.76 亿元、25.06 亿元、13.74 亿元。万科企业(02202)、中国海洋石油-R(80883)、比亚 迪股份-R(81211)的偏离值位居前三，分别为36.01%、35.40%、26.18%。 前十大沽空比率排行 | 股票名称 | 沽空金额 | 沽空比率↓ | 偏离值 | | --- | --- | --- | --- | | 比亚迪股份-R(81211) | 496.68 万元 | 96.88% | 26.18% | | 中国海洋石油-R(80883) | 57.37 万元 | 80.42% | 35.40% | | 美团-WR(83690) | 715.97 万元 | 75.34% | 15.02% | | 商汤-WR(80020) | 88.77 万元 | 66.55% | 13.10% | | 阿里巴巴-SWR(89988 ...

7月31日恒生指数下跌1.60%，南向资金全天合计成交金额为1704.75亿港元，其中，买入成交918.01亿 港元，卖出成交786.75亿港元，合计净买入金额131.26亿港元。具体来看，港股通（深）累计成交金额 616.04亿港元，买入成交335.63亿港元，卖出成交280.41亿港元，合计净买入金额55.22亿港元；港股通 （沪）累计成交金额1088.71亿港元，买入成交582.38亿港元，卖出成交506.34亿港元，合计净买入金额 76.04亿港元。 从连续性进行统计， 有3只股获南向资金连续3天以上净买入，连续净买入天数较多的有腾讯控股、阿 里巴巴-W、小米集团-W，连续净买入天数分别为6天、5天、5天。以其间净买入金额统计，净买入金 额最多的是小米集团-W，合计净买入为30.37亿港元，其次是腾讯控股合计净买入为27.05亿港元，阿里 巴巴-W合计净买入为26.73亿港元。 7月31日南向资金成交活跃股 | 代码 | 简称 | 成交金额（万港元） | 成交净买入（万港元） | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | 02800 | 盈富基金 | 2 ...

净买入盈富基金24.05亿、恒生中国企业17.82亿、美团-W 13.98亿、快手-W 13.83亿、阿里巴巴-W 10.43 亿、南方恒生科技9.73亿、小米集团-W 4.41亿、腾讯控股4.33亿、中芯国际2.21亿； 格隆汇7月31日｜南下资金今日净买入港股131.26亿港元。其中： 净卖出老铺黄金2.78亿、石药集团1.13亿。 据统计，南下资金已连续6日净买入腾讯，共计27.055亿港元；连续5日净买入阿里巴巴，共计26.7318亿 港元；连续5日净买入小米，共计30.3639亿港元。(格隆汇) ...

Core Insights - On July 31, 2025, Meituan-W (03690), Alibaba-W (09988), and Xiaomi Group-W (01810) were the top three companies by trading volume in the southbound section of the Hong Kong Stock Connect, with trading amounts of 4.049 billion, 3.790 billion, and 3.694 billion respectively [1][2] - In the southbound section of the Shenzhen-Hong Kong Stock Connect, Xiaomi Group-W (01810), Meituan-W (03690), and Tencent Holdings (00700) led the trading volume, with amounts of 2.438 billion, 2.300 billion, and 2.086 billion respectively [1][2] Southbound Trading Activity - The top three active companies in the southbound section of the Hong Kong Stock Connect were: - Meituan-W (03690) with a trading amount of 4.049 billion and a net buying amount of +1.196 billion - Alibaba-W (09988) with a trading amount of 3.790 billion and a net buying amount of +0.654 billion - Xiaomi Group-W (01810) with a trading amount of 3.694 billion and a net buying amount of +0.368 billion [2] - The top three active companies in the southbound section of the Shenzhen-Hong Kong Stock Connect were: - Xiaomi Group-W (01810) with a trading amount of 2.438 billion and a net buying amount of +0.736 billion - Meituan-W (03690) with a trading amount of 2.300 billion and a net buying amount of +0.202 billion - Tencent Holdings (00700) with a trading amount of 2.086 billion and a net buying amount of +0.336 billion [2]

Group 1: Market Overview - On July 31, the Hong Kong stock market saw a net inflow of 13.126 billion HKD from northbound trading, with 7.604 billion HKD from the Shanghai Stock Connect and 5.522 billion HKD from the Shenzhen Stock Connect [2] - The most bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Meituan-W (03690) [2][3] - The most sold stocks were Laopuhuangjin (06181), CSPC Pharmaceutical Group (01093), and Shandong Molong Petroleum Machinery (00568) [2] Group 2: Active Stocks - The top net bought stocks included Meituan-W (03690) with 2.622 billion HKD, Alibaba-W (09988) with 2.222 billion HKD, and Xiaomi Group-W (01810) with 2.031 billion HKD [3] - The top net sold stocks included Shandong Molong (00568) with 940 million HKD and CSPC Pharmaceutical Group (01093) with 891 million HKD [3] Group 3: ETF and Sector Insights - Northbound trading showed strong interest in ETFs, with the Tracker Fund of Hong Kong (02800) receiving a net inflow of 2.405 billion HKD, Hang Seng China Enterprises (02828) with 1.781 billion HKD, and Southern Hang Seng Technology (03033) with 973 million HKD [6] - The technology sector is highlighted as a significant part of the Hong Kong market, accounting for nearly one-third, with a focus on potential revaluation driven by technology [6] Group 4: Company-Specific News - Meituan-W (03690) received a net inflow of 13.98 billion HKD, while Kuaishou-W (01024) and Alibaba-W (09988) received 13.82 billion HKD and 10.43 billion HKD respectively [6] - Semiconductor company SMIC (00981) saw a net inflow of 2.21 billion HKD amid concerns regarding Nvidia's chip security issues [7] - Meitu Company (01357) received a net inflow of 15.3 million HKD, with Morgan Stanley raising its target price by 140% [7] Group 5: Performance Expectations - Laopuhuangjin (06181) faced a net outflow of 2.78 billion HKD, with analysts questioning the sustainability of its profit growth [8] - Analysts expect Laopuhuangjin's revenue to grow by 26% year-on-year next year, with adjusted net profit expected to rise by 30% [8] - Xiaomi Group-W (01810) received a net inflow of 441 million HKD, while CSPC Pharmaceutical Group (01093) and Shandong Molong (00568) faced net outflows [8]